NCT03873818View on ClinicalTrials.gov

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 21, 2019

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Malignant Neoplasm in the BrainMetastatic MelanomaPathologic Stage IV Cutaneous Melanoma AJCC v8

Interventions

BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER